20/20 Biolabs, Inc. Common Stock (AIDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, 20/20 Biolabs, Inc. Common Stock (AIDX) has a cash flow conversion efficiency ratio of -0.350x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-536.45K) by net assets ($1.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 20/20 Biolabs, Inc. Common Stock net asset quality index to measure how much of total assets are equity-financed.
20/20 Biolabs, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how 20/20 Biolabs, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check AIDX cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
20/20 Biolabs, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 20/20 Biolabs, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Morarjee Textiles Limited
NSE:MORARJEE
|
-0.006x |
|
Jowell Global Ltd.
NASDAQ:JWEL
|
-0.494x |
|
Bank Mayapada Internasional
JK:MAYA
|
-0.128x |
|
Huntsman Exploration Inc
V:HMAN
|
-0.733x |
|
ABM International Limited
NSE:ABMINTLLTD
|
0.002x |
|
Aterian Inc
NASDAQ:ATER
|
-0.069x |
|
Pryme BV
OL:PRYME
|
-1.603x |
|
PDZ Holdings Bhd
KLSE:6254
|
0.138x |
Annual Cash Flow Conversion Efficiency for 20/20 Biolabs, Inc. Common Stock (2016–2024)
The table below shows the annual cash flow conversion efficiency of 20/20 Biolabs, Inc. Common Stock from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see 20/20 Biolabs, Inc. Common Stock (AIDX) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.53 Million | $-2.60 Million | -1.694x | -56.91% |
| 2023-12-31 | $4.29 Million | $-4.63 Million | -1.080x | -274.38% |
| 2022-12-31 | $9.37 Million | $5.80 Million | 0.619x | +497.12% |
| 2021-12-31 | $6.89 Million | $-1.07 Million | -0.156x | +74.07% |
| 2020-12-31 | $3.39 Million | $-2.04 Million | -0.601x | +39.14% |
| 2019-12-31 | $2.15 Million | $-2.12 Million | -0.988x | -146.80% |
| 2018-12-31 | $3.28 Million | $-1.31 Million | -0.400x | +82.79% |
| 2017-12-31 | $456.18K | $-1.06 Million | -2.325x | +3.73% |
| 2016-12-31 | $784.36K | $-1.89 Million | -2.415x | -- |
About 20/20 Biolabs, Inc. Common Stock
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (… Read more